Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)
In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Today1d
Walmart gets a new logo and people are talking. Here's why
Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Regeneron (REGN – Research Report), with a ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
(Reuters) - Regeneron (NASDAQ: REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing ...
CapitaLand Investment expands global data centre portfolio with development of its first data centre in Japan
CapitaLand Investment Limited (CLI), a leading global real asset manager, has acquired a freehold land parcel in Osaka to ...
Nasdaq17d
First Week of March 21st Options Trading For Regeneron Pharmaceuticals (REGN)
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...
Morningstar17d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Regeneron Pharmaceuticals Inc. closed 42.65% below its 52-week high of $1,211.20, which the company achieved on August 27th.
Yahoo Finance22d
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money ...